Exercise May Improve Neurocognition in Schizophrenia

This article originally appeared here.
Share this content:
Exercise May Improve Neurocognition in Schizophrenia
Exercise May Improve Neurocognition in Schizophrenia

(HealthDay News) -- Aerobic exercise might boost neurocognitive function in people with schizophrenia, according to a small study published online March 23 in the Schizophrenia Bulletin.

The research included 33 schizophrenia patients who were randomly assigned to receive one of two treatments. One group was given standard psychiatric treatment (the control group). The other took part in a 12-week aerobic exercise program using active-play video games and standard exercise equipment. The patients in the exercise group also continued to receive standard psychiatric care.

By the end of the study period, aerobic fitness improved by 18 percent in the exercise group. It fell by 0.5 percent in the control group. Neurocognitive function improved by 15 percent in the exercise group and fell by 2 percent in the control group. "Our results indicate that poor aerobic fitness represents a modifiable risk factor for cognitive dysfunction in people with schizophrenia, for which aerobic exercise training offers a safe, non-stigmatizing, and side-effect-free intervention," lead author David Kimhy, Ph.D., of the New York State Psychiatric Institute in New York City, said in an institute news release.

The researchers said that a protein, brain-derived neurotrophic factor, which increases with physical activity, may be "a potential mechanism" for the exercise-related improvements in schizophrenia patients' mental function. "If replicated, our findings may lead to the integration of aerobic exercise into standard psychiatric treatment for people with schizophrenia and other severe mental health problems, Kimhy said.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths